What question did this study set out to answer?

This analysis aims to evaluate the efficacy of talquetamab in heavily pre-treated patients with systemic light-chain amyloidosis.

P67 | Talquetamab Induces Deep Responses in Heavily Pre-Treated Patients With Systemic Light-Chain Amyloidosis

View Full Paper

Ask AI

Bookmark

This analysis aims to evaluate the efficacy of talquetamab in heavily pre-treated patients with systemic light-chain amyloidosis.
Retrospective case-series including adults with biopsy-proven R/R AL amyloidosis.
Patients treated with talquetamab were analyzed across two centers.
Data collected on treatment history, response rates, and adverse events.
83% of patients achieved hematologic response, with all obtaining complete remission.
Median time to response was 26 days, with sustained MRD negativity in 3 of 3 patients tested.
Manageable adverse events included cytokine release syndrome and neurotoxicity without any new safety signals.

No takes yet. Share an insight, caveat, or question.

Retrospective case-series shows talquetamab improves outcomes in patients with R/R AL amyloidosis, suggesting effective treatment options are needed.

Shragai et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective case-series shows talquetamab improves outcomes in patients with R/R AL amyloidosis, suggesting effective treatment options are needed.